ESC Premium Access

Type of P2Y12 inhibitor at the acute stage and one-year mortality in acute myocardial infarction. The FAST-MI programme

Presentation

About the speaker

Professor Nicolas Danchin

AP-HP - European Hospital Georges Pompidou, Paris (France)
13 presentations
0 follower

5 more presentations in this session

A head-to-head comparison of uniform prasugrel treatment vs. clopidogrel treatment for confirmed responders in acute coronary syndrome patients: results from the randomized TROPICAL-ACS trial

Speaker: Doctor R. Hein (Munich, DE)

Thumbnail

Prasugrel vs Ticagrelor in patients with acute coronary syndrome and diabetes: a propensity match substudy of RENAMI

Speaker: Doctor M. Bertaina (Turin, IT)

Thumbnail

Next generation P2Y12 inhibitors improve survival in ACS: An analysis from the British Cardiovascular Intervention Society database.

Speaker: Doctor H. Contractor (Manchester, GB)

Thumbnail

Prognostic impact of the new P2Y12 (ticagrelor and prasugrel) versus clopidogrel in acute coronary syndrome patients in relation to renal function

Speaker: Mrs M. Castineira Busto (Vigo, ES)

Thumbnail

The OPTIDUAL trial: long term follow-up

Speaker: Professor G. Helft (Paris, FR)

Thumbnail

Access the full session

Oral P2Y12 inhibitors in acute coronary syndromes: are they all equal?

Speakers: Professor N. Danchin, Doctor R. Hein, Doctor M. Bertaina, Doctor H. Contractor, Mrs M. Castineira Busto...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Related content

ESC Premium Access

How to interpret results from spiroergometry.

29 August 2021

This platform is supported by

logo Novo Nordisk